Infectious Disease Diagnostics Testing Market Research Explores Growth Within A $65.49 Billion Opportunity

The infectious disease diagnostics testing market is positioned for significant expansion in the coming years, driven by increasing global health challenges and technological advancements. As the world continues to face evolving threats from infectious diseases, the need for faster and more accurate diagnostic tools becomes essential. This overview explores the market's growth outlook, key players shaping the industry, emerging trends, and the segmentation that defines this vital healthcare sector.

Strong Growth Outlook for the Infectious Disease Diagnostics Testing Market Size Through 2030
The infectious disease diagnostics testing market is anticipated to experience robust growth, reaching a market size of $65.49 billion by 2030. This expansion is expected at a compound annual growth rate (CAGR) of 9.0%. Factors contributing to this growth include the increasing risk of global pandemics, heightened demand for rapid diagnostic methods, rising investments in healthcare diagnostics, expansion of disease surveillance efforts, and the growing prevalence of tropical and viral diseases worldwide. The forecast period is also characterized by trends such as the rising need for early and rapid disease detection, broader adoption of point-of-care infectious disease tests, increased application of molecular diagnostic techniques for pinpointing pathogens, and a stronger emphasis on large-scale screening and surveillance programs.

Download a free sample of the infectious disease diagnostics testing market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15831&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Key Players Leading the Infectious Disease Diagnostics Testing Industry
Several well-established corporations dominate the infectious disease diagnostics testing landscape. These include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton dic*kinson and Company, Quest Diagnostics Incorporated, Grifols S.A., Hologic Inc., PerkinElmer Inc., bioMérieux SA, Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., DiaSorin SpA (Luminex), Seegene Inc., Ortho Clinical Diagnostics Inc., OraSure Technologies Inc., Meridian Bioscience Inc., and Trinity Biotech PLC. A notable development occurred in July 2024 when Roche, based in Switzerland, acquired LumiraDx's point-of-care technology business. This strategic move aims to enhance Roche's presence in decentralized and primary care testing by integrating LumiraDx's innovative multi-assay platform, which currently offers immunoassay and clinical chemistry capabilities with potential for molecular diagnostics. LumiraDx is a UK-based specialist in infectious disease diagnostics.

Innovative Trends Shaping the Infectious Disease Diagnostics Testing Sector
The infectious disease diagnostics market is witnessing rapid technological progress as leading companies develop tools to detect infections quickly and accurately. Diagnosing infectious diseases involves identifying bacteria, viruses, or parasites to guide effective treatment. For example, in January 2025, QIAGEN, a biotechnology firm from Germany, introduced new QIAstat-Dx syndromic testing panels in India, including the Gastrointestinal Panel 2 and Meningitis/Encephalitis Panel. These joined the already approved Respiratory SARS-CoV-2 Panel authorized by India's Central Drugs Standard Control Organization (CDSCO). The QIAstat-Dx system employs multiplex real-time PCR technology with single-use cartridges that can detect multiple pathogens simultaneously, providing results in approximately one hour for gastrointestinal infections and 80 minutes for infections of the central nervous system. This advancement allows faster and more precise diagnosis compared to conventional methods, enabling timely therapy, better patient outcomes, and reduced strain on healthcare systems. The system also features customizable configurations and cloud-based connectivity for remote monitoring and efficient data handling.

View the full infectious disease diagnostics testing market report:
https://www.thebusinessresearchcompany.com/report/infectious-disease-diagnostics-testing-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Global Market Segmentation Overview of Infectious Disease Diagnostics Testing
The infectious disease diagnostics testing market is segmented into several categories to address diverse diagnostic needs. By type, the market includes Molecular Diagnostic Tests and Point of Care Tests (POCT) for infectious diseases. Molecular diagnostic tests are further divided into Polymerase Chain Reaction (PCR) tests and Nucleic Acid Amplification Tests (NAATs). POCT encompasses lateral flow assays, rapid antigen tests, immunoassays, and portable PCR devices. In terms of application, the market covers respiratory infections, human immunodeficiency virus (HIV), healthcare-associated infections (HAIs), sexual health, and tropical diseases. The end-user categories include diagnostic laboratories as well as hospitals and clinics, reflecting the healthcare settings where these tests are most frequently utilized.

What's new in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel dashboards
• Market hotspots infographics
• Key technologies and future trends
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.